| Filter Options | |||||
|---|---|---|---|---|---|
| Public title | Scientific title | Subject ID | |||
| Registration Status | Registration number | Secondary ID | |||
| Applicant | Study leader | Year | |||
| Primary sponsor | Secondary sponsor | Source(s) of funding | |||
| Target disease | Target disease code | Study type | |||
| Study phase | Study design | Study execute time |
From To |
||
| Recruiting status | Gender | Sign the informed consent | |||
| Countries of recruitment and research settings |
Nation(Area)：Province：City： Institution：Level of the institution： |
||||
| Intervention | Intervention code | Approved by ethic committee | |||
|
Calculated Results after the Study Completed public access |
Statistical results after completion of the test file upload |
||||
| More Options | |||||
719 trials have been registered
| Historical versions | Registration number | Public title | Type | Registration time |
|---|---|---|---|---|
| Historical Versions | ChiCTR2000039462 |
A phase II clinical trial for inactivated SARS-CoV-2 (COVID-19) Vaccine (Vero Cells) Jiangsu Provincial Center for Disease Control and Prevention(Public Health Research Institute of Jiangsu Province) |
Prevention | 2020/10/28 |
| Historical Versions | ChiCTR2000039369 |
Xiangyang Central Hospital |
Interventional | 2020/10/24 |
| Historical Versions | ChiCTR2000039364 |
The clinical characteristics and the etiology of COVID-19 infected patients with myocardial damage Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
Observational | 2020/10/24 |
| Historical Versions | ChiCTR2000039212 |
Shulan (Hangzhou) Hospital |
Prevention | 2020/10/22 |
| Historical Versions | ChiCTR2000039002 |
Navy Medical University |
Interventional | 2020/10/13 |
| Historical Versions | ChiCTR2000039000 |
China National Biotec Group Co.Ltd |
Interventional | 2020/10/13 |
| Historical Versions | ChiCTR2000038943 |
Outcomes of and Prognosis Factors for COVID-19 Patients: An Observational Study Xiangya Hospital, Central South University |
Observational | 2020/10/10 |
| Historical Versions | ChiCTR2000038865 |
None |
Observational | 2020/10/07 |
| Historical Versions | ChiCTR2000038804 |
A phase I clinical trial for inactivated SARS-CoV-2 Vaccine(Vero Cells) Jiangsu Provincial Center for Disease Control and Prevention(Public Health Research Institute of Jiangsu Province) |
Prevention | 2020/10/02 |
| Historical Versions | ChiCTR2000038740 |
Beijing University of Chinese Medicine Third Affiliated Hospital |
Interventional | 2020/09/30 |
r